LYMEPOLICYWONK: Patient Centered Research and Lyme—An idea whose time has come?

Byldoadmin

You may recall that Embers and colleagues found persistence of the Lyme bacteria in monkeys following the Klempner “long-term” antibiotic treatment protocol (hotly contested by Dr. Baker who oversaw the research trial when he was at the NIH), persistence following the IDSA 28 day antibiotic treatment regimen, and faulty testing.  If you’ve missed the fireworks, they’re  here.

If you want to listen to Dr. Chalmers’ interview, it is here.

The LYME POLICY WONK blog is written by Lorraine Johnson, JD, MBA, who is the Chief Executive Officer of LymeDisease.org, formerly CALDA. Contact her at lbjohnson@lymedisease.org.

 

Similar Posts

  • |

    LYMEPOLICYWONK: The Economic Impact and Burden of Lyme Disease—A Wake Up Call to Policy Makers

    I was honored to speak at the “What’s NEXT” Lyme forum, hosted by Congressman Chris Gibson at Skidmore College in Saratoga Springs, New York on May 21, 2012. It was a fabulous event and included some terrific presentations. My presentation (which is now posted on our website) highlighted the results of our 2009 survey of over 4,000 patients with chronic Lyme Disease that was published in Health Policy last year. In it, I point out the serious personal and economic consequences of the failed policies of the Infectious Diseases Society of America (IDSA)—policies that have resulted in both an alarming crisis of compassion and an intolerable level of fiscal irresponsibility.

  • LYMEPOLICYWONK: Was the Last Decade of Lyme Research a Cover-Up? Baker and the Embers Study Revisited.

    Two weeks ago, I posted a blog regarding the IDSA stealth front organization, the American Lyme Disease Foundation (ALDF). I highlighted the fact that Dr. Phil Baker, who was responsible for overseeing the Lyme clinical trials at the National Institute of Health (NIH) prior to his retirement, is now the Executive Director at the ALDF. I also questioned the handling of two companion studies during his tenure at NIH. One (Klempner), which found no persistent infection, was rushed to publication, while its companion monkey trial (Embers) languished for ten long years. During the interim, the Klempner trial was heavily promoted by the IDSA to deny patients treatment for chronic Lyme disease while no one mentioned that the companion study, the Embers trial, was still pending. Dr. Baker protested that he had nothing to do with the delay. However, I pointed out that he had an ethical obligation to accurately characterize the uncertain state of the science while the Embers companion study was pending. Dr. Baker now goes to great lengths to explain the delay (see below), and I respond.

  • LYMEPOLICYWONK: IDSA APRIL DEADLINE

    We are all concerned about the latest report from the IDSA statement that they plan to issue their final report regarding the IDSA guidelines review panel by the end of April. We are particularly concerned about whether the IDSA has corrected its voting violations. There may be other actions for the community to take as this unfolds, but right now, it is critical that we continue keeping the pressure on for other state AG’s to send letters to the IDSA (IMPORTANT: cc the CT AG) expressing concern about the voting violations and asking for compliance. Letters from legislators would also help spotlight the importance of the issue. Information on how to do this is posted on CALDA’s website along with the press release issued by CALDA, TFL and the LDA.

  • Bias and patient autonomy—what’s the connection

    Everyone is entitled to their own opinion. So why do we care about bias in medical guidelines? Because opinion should not dictate patient care. Think of the prostate cancer patient who sees the surgeon who recommends surgery, the radiologist who recommends radiation treatment, and the internist who recommends watchful waiting. Everyone knows that one’s position depends on where one sits. The surgeon may genuinely prefer surgery and when he recommends it to his patient, the patient realizes that he is, after all, talking with a surgeon and that surgeons are likely to favor surgery. He also knows that he can walk down the street a bit and talk with the radiologist and get his perspective. The point is that even though the patient is given conflicting advice, at the end of the day the decision is his. He chooses among treatment options and the physicians respect his decision. This is called autonomy—a recognition that patients are entitled to make choices among health care options.

  • LYMEPOLICYWONK: And, the Number Is? 5,200 Responses! IDSA Guidelines and Patient Preference Survey

    Let me thank everyone who responded to the Patient Preferences Survey! We have drawn over 5,200 responses, which is just simply fabulous. We will now start the process of reviewing the responses with an eye toward publication of the results. Our last survey was published in Health Policy, a widely respected peer reviewed journal. Those results now help inform the base of knowledge of the access to care problems that Lyme patients face. Our goal with these surveys is to open the space for conversations in the public health arena about what is really going on with Lyme patients from their perspective. We are trying to give voice to the patient community, which is all to often completely ignored in conversations about Lyme disease. Your willingness to participate in these surveys allows us to do that. So hats off to you for being so vocal and letting us know your views.